Literature DB >> 33135460

Assessment of individual and standardized glucagon kinetics in healthy humans.

Marcello C Laurenti1, Adrian Vella1, Jon D Adams1, Daniel J Schembri Wismayer1, Aoife M Egan1, Chiara Dalla Man2.   

Abstract

Impaired glucose tolerance arises out of impaired postprandial insulin secretion and delayed suppression of glucagon. These defects occur early and independently in the pathogenesis of prediabetes. Quantification of the contribution of α-cell dysfunction to glucose tolerance has been lacking because knowledge of glucagon kinetics in humans is limited. Therefore, in a series of experiments examining the interaction of glucagon suppression with insulin secretion we studied 51 nondiabetic subjects (age = 54 ± 13 yr, BMI = 28 ± 4 kg/m2). Glucose was infused to mimic the systemic appearance of an oral challenge. Somatostatin was used to inhibit endogenous hormone secretion. 120 min after the start of the experiment, glucagon was infused at 0.65 ng/kg/min. The rise in glucagon concentrations was used to estimate its kinetic parameters [volume of distribution (Vd), half-life (t1/2), and clearance rate (CL)]. A single-exponential model provided the best fit for the data, and individualized kinetic parameters were estimated: Vd = 8.2 ± 2.7 L, t1/2 = 4 ± 1.1 min, CL = 1.4 ± 0.33 L/min. Stepwise linear regression was used to correlate Vd with BMI and sex (R2adj = 0.44), whereas CL similarly correlated with lean body mass or BSA (both R2 = 0.28). This enabled the development of a population-based model using anthropometric characteristics to predict Vd and CL. These data demonstrate that it is feasible to derive glucagon kinetic parameters from anthropometric characteristics, thereby enabling quantitation of the rate of glucagon appearance in the systemic circulation in large populations.NEW & NOTEWORTHY State-of-the-art measurement of insulin secretion in humans is accomplished by deconvolution of peripheral C-peptide concentrations using population-derived parameters of C-peptide kinetics. In contrast, knowledge of the kinetic parameters of glucagon in humans is lacking so that measurement of glucagon secretion to date is largely qualitative. This series of experiments enabled measurement of glucagon kinetics in 51 subjects, and subsequently, stepwise linear regression was used to correlate these parameters with anthropometric characteristics. This enabled the development of a population-based model using anthropometric characteristics to predict the volume of distribution and the rate of clearance. This is a necessary first step in the development of a model to quantitate of glucagon secretion and action (and its contribution to glucose tolerance) in large populations.

Entities:  

Keywords:  clearance; glucagon; impaired glucose tolerance; prediabetes; α-cell

Mesh:

Substances:

Year:  2020        PMID: 33135460      PMCID: PMC8194411          DOI: 10.1152/ajpendo.00488.2020

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  28 in total

1.  Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.

Authors:  A Vella; P Shah; R Basu; A Basu; J J Holst; R A Rizza
Journal:  Diabetes       Date:  2000-04       Impact factor: 9.461

2.  Impact of lack of suppression of glucagon on glucose tolerance in humans.

Authors:  P Shah; A Basu; R Basu; R Rizza
Journal:  Am J Physiol       Date:  1999-08

3.  Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans.

Authors:  Juris J Meier; Johannes D Veldhuis; Peter C Butler
Journal:  Diabetes       Date:  2005-06       Impact factor: 9.461

4.  Performance of individually measured vs population-based C-peptide kinetics to assess β-cell function in the presence and absence of acute insulin resistance.

Authors:  Ron T Varghese; Chiara Dalla Man; Marcello C Laurenti; Francesca Piccinini; Anu Sharma; Meera Shah; Kent R Bailey; Robert A Rizza; Claudio Cobelli; Adrian Vella
Journal:  Diabetes Obes Metab       Date:  2017-09-27       Impact factor: 6.577

5.  Proglucagon processing in porcine and human pancreas.

Authors:  J J Holst; M Bersani; A H Johnsen; H Kofod; B Hartmann; C Orskov
Journal:  J Biol Chem       Date:  1994-07-22       Impact factor: 5.157

6.  Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation.

Authors:  Kristine Færch; Dorte Vistisen; Giovanni Pacini; Signe S Torekov; Nanna B Johansen; Daniel R Witte; Anna Jonsson; Oluf Pedersen; Torben Hansen; Torsten Lauritzen; Marit E Jørgensen; Bo Ahrén; Jens Juul Holst
Journal:  Diabetes       Date:  2016-08-08       Impact factor: 9.461

7.  Pharmacokinetics of intranasal, intramuscular and intravenous glucagon in healthy subjects and diabetic patients.

Authors:  A E Pontiroli; A Calderara; M G Perfetti; S R Bareggi
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  The essential role of glucagon in the pathogenesis of diabetes mellitus.

Authors:  R H Unger; L Orci
Journal:  Lancet       Date:  1975-01-04       Impact factor: 79.321

9.  TCF7L2 Genotype and α-Cell Function in Humans Without Diabetes.

Authors:  Meera Shah; Ron T Varghese; John M Miles; Francesca Piccinini; Chiara Dalla Man; Claudio Cobelli; Kent R Bailey; Robert A Rizza; Adrian Vella
Journal:  Diabetes       Date:  2015-11-02       Impact factor: 9.461

10.  Diabetes-Associated Variation in TCF7L2 Is Not Associated With Hepatic or Extrahepatic Insulin Resistance.

Authors:  Ron T Varghese; Ivan Viegas; Cristina Barosa; Catia Marques; Meera Shah; Robert A Rizza; John G Jones; Adrian Vella
Journal:  Diabetes       Date:  2016-01-28       Impact factor: 9.461

View more
  2 in total

1.  Insulin secretion and action and the response of endogenous glucose production to a lack of glucagon suppression in nondiabetic subjects.

Authors:  Jon D Adams; Aoife M Egan; Marcello C Laurenti; Daniel Schembri Wismayer; Kent R Bailey; Claudio Cobelli; Chiara Dalla Man; Adrian Vella
Journal:  Am J Physiol Endocrinol Metab       Date:  2021-10-18       Impact factor: 4.310

2.  Differential contribution of alpha and beta cell dysfunction to impaired fasting glucose and impaired glucose tolerance.

Authors:  Jacob D Kohlenberg; Marcello C Laurenti; Aoife M Egan; Daniel Schembri Wismayer; Kent R Bailey; Claudio Cobelli; Chiara Dalla Man; Adrian Vella
Journal:  Diabetologia       Date:  2022-09-16       Impact factor: 10.460

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.